Protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in streptozotocin-induced diabetic rats

( views:65, downloads:0 )
Yan Li()
Yang Rongze()
Cheng Hua()
Fu Zuzhi()
Zhong Guangshu()
Yan Tang()
Journal Title:
Volume 111, Issue 04, 1998
Key Word:

Abstract: Objectives To evaluate the protective effect of the angiotensin-converting enzyme inhibitor perindopril on diabetic glomerulopathy in rats with experimentally induced diabetes and explore its possible mechanisms. Methods Ninety-two adult male Wistar rats were randomly allocated into diabetes mellitus (DM), diabetes mellitus + perindopril (DMP) and control (C) groups. According to the duration of diabetes or observation (1, 3, 6 months), each group was randomly subdivided into DM1, DM3, DM6; DMP1, DMP3, DMP6; and C1, C3, C6 groups. Diabetes was induced by intraperitoneal injection of streptozotocin. The rats in the DMP groups received perindopril 1 mg*kg-1*d-1, through gastric intubation. Urinary protein excretion rate was determined by the method of Coomassie brilliant blue. Plasma renin activity, renal tissue renin activity, and plasma and renal tissue angiotensin Ⅱ concentration were assayed by radioimmunoassay (RIA). Renal tissue total RNA was extracted by the Chomezymskis AGPC method. Renal angiotensinogen mRNA expression level was assessed by slot blot hybridization using a full length rat angiotensinogen cDNA probe labelled with 32P-dCTP and a random primer.Results There was increased activity of the renin angiotensin system in diabetic rats. Perindopril decreased proteinuria and delayed the progression of glomerular basement membrane thickening. However, it did not reduce the expansion of the mesangial matrix (P<0.05). Renin activity increased and angiotensin Ⅱ concentration decreased significantly in both plasma and renal tissue in diabetes+perindopril groups (P<0.05).Conclusions Perindopril may help prevent the progression of diabetic glomerulopathy, and the inhibition of renin angiotensin system activity may be a mechanism for this action.

  • [1]Yang RZ, Yan L, Fu ZZ, et al. The mRNA expressions of angiotensinogen and TGF-β1 in the kidney of STZ-diabetic rats. Chin J Diabetes 1995; 3(1):33.
  • [2]Correa-Rotter R, Hostetter TH, Rosenberg ME. Renin and angiotensinogen gene expression in experimental diabetes mellitus. Kidney Int 1992; 41:798.
  • [3]Zhu D, Yu BJ, Qin WW, et al. Quantitative glomerular morphology of the normal and diabetic rat kiney. Acad J Sun Yat-sen Univ Med Sci 1990; 11(3):38.
  • [4]Willa AH. Effect of the Renin-Angiotensin system in the vascular disease of type Ⅱ diabetes mellitus. Am J Med 1992; 92(Suppl 4b)13s.
  • [5]Cooper ME, Allen TJ, Macmillan PA, et al. Enalapril retarded glomerular basement membrane thickening and albuminuria in the diabetic rat. Diabetologia 1989; 32:326.
  • [6]Brown SA, Walton CL, Crawford P, et al. Long term effects of antihypertensive regiments on renal hemodynamics and proteinuria. Kidney Int 1993; 43:1210.
  • [7]Cooper ME, Allen TJ, O'Brien RC, et al. Nephropathy in model combining genetic hypertension with experimental diabetes. Diabetes 1990; 30:1575.
  • [8]Cooper ME, Rumble JR, Allen TJ, et al. Antihypertensive therapy in a model combining spontaneous hypertension with diabetes.Kidney Int 1992; 41:898.
  • [9]Zata R, Dunn BR, Meyer TW, et al. Prevention of diabetic glomerulopathy by pharmacological amelioration of glomerular capillary hypertension. J Clin Invest 1986; 77(6):1925.
  • [10]Steffes MW, Mauer SM. Diabetic glomerulopathy in man and experimental animal models. Int Rev Exp Pathol 1984; 26:147.
  • [11]Petersen J, Ross J, Rabkin R. Effect of insulin therapy on established diabetic nephropathy in rats. Diabetes 1988; 37:1346.
WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615